Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Investing.com - Raymond (NSE:RYMD) James raised its price target on HealthEquity, Inc (NASDAQ:HQY) to $120.00 from $115.00 while maintaining a Strong Buy rating, citing progress in addressing fraud issues and strong financial performance. According to InvestingPro data, the company has received positive earnings revisions from 8 analysts, with an average price target of $130, suggesting further upside potential. The company’s market capitalization currently stands at $8.8 billion.
The healthcare financial services company reported 15% total revenue growth year-over-year in the first quarter of fiscal 2026, driven by 29% custodial revenue growth and 14% interchange revenue growth. The adjusted EBITDA margin expanded 155 basis points year-over-year to 42.4%, reflecting efficiency gains from investments in artificial intelligence. InvestingPro analysis shows the company maintains strong financial health with a "GREAT" overall score, supported by a robust gross profit margin of 65.5% and impressive revenue growth of 19.2% over the last twelve months.
Direct fraud service costs decreased to $3 million in the first quarter of fiscal 2026 compared with $11 million in the fourth quarter of fiscal 2025. Management expects these elevated service costs to normalize in the second half of fiscal 2026 and targets an annual run rate of approximately $3 million going forward.
The annualized yield on HSA cash was 3.5% in the first quarter of fiscal 2026 compared with 2.9% in the same period last year. For the second quarter, management has locked in a roughly 4.0% yield on $500 million of the $5.7 billion cash set to mature through fiscal 2027 to hedge against potential interest rate volatility.
The One Big Beautiful Bill Act, signed into law on July 4, 2025, includes provisions expanding HSA usage by allowing them to be paired with bronze and catastrophic ACA plans, which Raymond James believes could expand the potential number of total industry HSAs by up to 5 million or more accounts. For deeper insights into HealthEquity’s market position and growth potential in the expanding HSA industry, InvestingPro subscribers can access the comprehensive Pro Research Report, which includes detailed analysis of the company’s competitive advantages and growth drivers.
In other recent news, HealthEquity, Inc. reported a strong fiscal first-quarter performance, with revenue reaching $330.8 million, marking a 15% increase compared to the previous year. This figure surpassed both analyst estimates and consensus expectations. The company’s adjusted EBITDA rose by 19% year-over-year to $140.2 million, exceeding projections from several firms, including BTIG and Citizens JMP. HealthEquity has also raised the lower end of its fiscal 2026 revenue guidance and increased the midpoint of its adjusted EBITDA guidance by $5 million.
In response to these results, multiple analysts have maintained positive ratings on HealthEquity. Mizuho (NYSE:MFG) reiterated an Outperform rating, while KeyBanc reaffirmed an Overweight rating. BTIG also maintained a Buy rating, citing the company’s strong earnings performance. Meanwhile, Goldman Sachs maintained a Neutral rating, noting the company’s improved gross margin trajectories but expressing concerns over slowing organic HSA account growth. Citizens JMP raised its price target for HealthEquity to $117, reflecting optimism about the company’s stock potential following its robust financial results. Additionally, recent legislative developments, including the Senate’s passage of a Budget Reconciliation bill with pro-HSA provisions, are expected to positively impact HealthEquity’s market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.